Figure 3g shows that there is a 10-fold increase in the median Six1 expression in cell lines that are resistant to Nutlin-3. However, increased Six1 expression does not correlate with resistance to other breast cancer therapies, including cisplatin, doxorubicin or paclitaxel, in this same data set, suggesting that it does not induce global drug resistance, but is specific to MDM2-targeted therapies (Supplementary Fig. 10). Here, SIX1 is linked to breast cancer.